These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8471326)

  • 1. Curability of advanced Burkitt's lymphoma in children by intensive short-term chemotherapy.
    Gasparini M; Rottoli L; Massimino M; Gianni MC; Ballerini E; Ravagnani F; Pupa S; Fossati-Bellani F
    Eur J Cancer; 1993; 29A(5):692-8. PubMed ID: 8471326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
    Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
    J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
    Schwenn MR; Blattner SR; Lynch E; Weinstein HJ
    J Clin Oncol; 1991 Jan; 9(1):133-8. PubMed ID: 1985162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
    Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
    J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcome in adult B-cell acute lymphoblastic leukemia.
    Hoelzer D; Ludwig WD; Thiel E; Gassmann W; Löffler H; Fonatsch C; Rieder H; Heil G; Heinze B; Arnold R; Hossfeld D; Büchner T; Koch P; Freund M; Hiddemann W; Maschmeyer G; Heyll A; Aul C; Faak T; Kuse R; Ittel TH; Gramatzki M; Diedrich H; Kolbe K; Fuhr HG; Fischer K; Schadeck-Gressel C; Weiss A; Strohscheer I; Metzner B; Fabry U; Gökbuget N; Völkers B; Messerer D; Uberla K
    Blood; 1996 Jan; 87(2):495-508. PubMed ID: 8555471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
    Adde M; Shad A; Venzon D; Arndt C; Gootenberg J; Neely J; Nieder M; Owen W; Seibel N; Wilson W; Horak ID; Magrath I
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):33-9; discussion 45-8. PubMed ID: 9578060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
    Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
    Di Nicola M; Carlo-Stella C; Mariotti J; Devizzi L; Massimino M; Cabras A; Magni M; Matteucci P; Guidetti A; Gandola L; Gianni AM
    Br J Haematol; 2004 Sep; 126(6):815-20. PubMed ID: 15352985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
    Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
    Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol.
    Todeschini G; Tecchio C; Degani D; Meneghini V; Marradi P; Balter R; Zanotti R; Ricetti M; Franchini M; Perona G
    Ann Oncol; 1997; 8 Suppl 1():77-81. PubMed ID: 9187436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.
    Lacasce A; Howard O; Lib S; Fisher D; Weng A; Neuberg D; Shipp M
    Leuk Lymphoma; 2004 Apr; 45(4):761-7. PubMed ID: 15160953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
    Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
    Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study.
    Bowman WP; Shuster JJ; Cook B; Griffin T; Behm F; Pullen J; Link M; Head D; Carroll A; Berard C; Murphy S
    J Clin Oncol; 1996 Apr; 14(4):1252-61. PubMed ID: 8648381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
    Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
    Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of moderate dose combination chemotherapy in Burkitt's lymphoma.
    Patel JG; Pandita R; al-Jazzaf H; Mechl Z; al-Jarallah MA
    Neoplasma; 1993; 40(3):185-8. PubMed ID: 8350967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).
    Bernstein JI; Coleman CN; Strickler JG; Dorfman RF; Rosenberg SA
    J Clin Oncol; 1986 Jun; 4(6):847-58. PubMed ID: 3711961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cyclophosphamide and intermediate-dose methotrexate for the treatment of far-advanced Burkitt's lymphoma.
    Brecher ML; Gardner RV; Ettinger LJ; Tebbi CK; Green DM; Freeman AI
    Am J Pediatr Hematol Oncol; 1985; 7(2):117-24. PubMed ID: 3842557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.